JPMorgan raised the firm’s price target on Amicus (FOLD) to $19 from $18 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus price target raised to $11 from $9 at Goldman Sachs
- Amicus Therapeutics Reports Strong Q3 2025 Results
- Amicus Therapeutics Reports Strong Q3 Earnings Growth
- Amicus’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Analyst
- Amicus Therapeutics: Strong Q3 Performance and Strategic Advancements Justify Buy Rating